Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04956575 · ClinicalTrials.gov registry record · Phase 1
A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
A Phase 1 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 885
- Enrollment target
NCT04956575 is a Phase 1 study that has completed, run by ModernaTX. The registered enrollment target is 885 participants.
The verdict
NCT04956575, a Phase 1 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 885 participants
- Enrollment target
Study Summary
The study comprises 3 parts: Phase 1/2, Phase 2 Northern Hemisphere (NH), and Phase 2 extension. The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1010 vaccine.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1010
- BIOLOGICAL Active Comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 885 participants |
| Start Date | 2021-07-06 |
| Est. Completion | 2022-09-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04956575
The ClinicalTrials.gov registry entry for NCT04956575 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 885 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04956575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04956575 about?
NCT04956575 is a clinical study titled "A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults". The study comprises 3 parts: Phase 1/2, Phase 2 Northern Hemisphere (NH), and Phase 2 extension. The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1010 vaccine.
What is the current status of trial NCT04956575?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 885 participants. The study started on 2021-07-06. Estimated completion is 2022-09-27.
What interventions are being tested in trial NCT04956575?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1010 (BIOLOGICAL), Active Comparator (BIOLOGICAL).
Who is sponsoring clinical trial NCT04956575?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.